menu
    • menu
    [{"orgOrder":0,"company":"Shionogi","sponsor":"QuatRx Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Steroid","year":"2012","type":"Inapplicable","leadProduct":"Ospemifene","moa":"Estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shionogi \/ QuatRx Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Shionogi \/ QuatRx Pharmaceuticals"},{"orgOrder":0,"company":"Shionogi","sponsor":"QuatRx Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Steroid","year":"2012","type":"Inapplicable","leadProduct":"Ospemifene","moa":"Estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shionogi \/ QuatRx Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Shionogi \/ QuatRx Pharmaceuticals"},{"orgOrder":0,"company":"Shionogi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Steroid","year":"2015","type":"Inapplicable","leadProduct":"Ospemifene","moa":"Estrogen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shionogi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shionogi \/ Undisclosed"},{"orgOrder":0,"company":"Duchesnay","sponsor":"Plushcare","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CANADA","productType":"Steroid","year":"2020","type":"Partnership","leadProduct":"Ospemifene","moa":"Estrogen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Duchesnay","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duchesnay \/ Plushcare","highestDevelopmentStatusID":"15","companyTruncated":"Duchesnay \/ Plushcare"}]

    Find Clinical Drug Pipeline Developments & Deals for Ospemifene

    Menu

    Ospemifene

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Duchesnay

                            Canada arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Duchesnay

                            Canada arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ospemifene

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Sponsor : Plushcare

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Duchesnay Usa & Plushcare Announce a New Partnership to Facilitate Access to Healthcare for Menopausal Women T...

                            Details : The aim of this partnership is to provide Duchesnay USA's Osphena® (ospemifene) to women suffering from vaginal symptoms related to menopause, with the possibility of having this conversation with a healthcare provider in the comfort and privacy of the...

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Undisclosed

                            May 19, 2020

                            Lead Product(s) : Ospemifene

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Sponsor : Plushcare

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Shionogi

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Shionogi

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ospemifene

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate Ospemifene in Patients With Moderate to Severe Vaginal Dryness Due to Menopause

                            Details : Ospemifene is a Steroid drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Vaginal Dryness.

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            December 23, 2015

                            Lead Product(s) : Ospemifene

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Shionogi

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Shionogi

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ospemifene

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : QuatRx Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrop...

                            Details : Ospemifene is a Steroid drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Atrophy.

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            April 26, 2012

                            Lead Product(s) : Ospemifene

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : QuatRx Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Shionogi

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Shionogi

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ospemifene

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : QuatRx Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in ...

                            Details : Ospemifene is a Steroid drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Atrophy.

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            April 26, 2012

                            Lead Product(s) : Ospemifene

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : QuatRx Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth